Latest news with #iRhythm
Yahoo
06-08-2025
- Business
- Yahoo
Zimmer Biomet (ZBH) Q2 Earnings: What To Expect
Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting earnings this Thursday before the bell. Here's what you need to know. Zimmer Biomet beat analysts' revenue expectations by 0.7% last quarter, reporting revenues of $1.91 billion, up 1.1% year on year. It was a slower quarter for the company, with a miss of analysts' full-year EPS guidance estimates. Is Zimmer Biomet a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Zimmer Biomet's revenue to grow 5.4% year on year to $2.05 billion, improving from the 3.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.98 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Zimmer Biomet has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.6% on average. Looking at Zimmer Biomet's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. CONMED delivered year-on-year revenue growth of 3.1%, beating analysts' expectations by 1.2%, and iRhythm reported revenues up 26.1%, topping estimates by 7.3%. CONMED traded up 1.8% following the results while iRhythm was also up 17.6%. Read our full analysis of CONMED's results here and iRhythm's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Zimmer Biomet's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $107.79 (compared to the current share price of $92.98). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
04-08-2025
- Business
- Yahoo
Masimo (MASI) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings this Tuesday afternoon. Here's what investors should know. Masimo beat analysts' revenue expectations by 1.1% last quarter, reporting revenues of $372 million, up 9.5% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' constant currency revenue estimates but a significant miss of analysts' full-year EPS guidance estimates. Is Masimo a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Masimo's revenue to grow 7.2% year on year to $368.7 million, a reversal from the 24.5% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.22 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Masimo has missed Wall Street's revenue estimates six times over the last two years. Looking at Masimo's peers in the patient monitoring segment, some have already reported their Q2 results, giving us a hint as to what we can expect. iRhythm delivered year-on-year revenue growth of 26.1%, beating analysts' expectations by 7.3%, and DexCom reported revenues up 15.2%, topping estimates by 2.8%. iRhythm traded up 17.6% following the results while DexCom was down 9.3%. Read our full analysis of iRhythm's results here and DexCom's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the patient monitoring stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Masimo is down 3.3% during the same time and is heading into earnings with an average analyst price target of $184.43 (compared to the current share price of $157.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Business Insider
15-07-2025
- Business
- Business Insider
BTIG maintains iRhythm estimates after CMS fee schedule proposal
BTIG analyst Marie Thibault reiterated a Buy rating and $165 price target on iRhythm (IRTC) Technologies after the Centers for Medicare & Medicaid published its CY26 Physician Fee Schedule Proposal, under which payment rates would be flat for long-term monitoring mobile cardiac telemetry reimbursement would get a low-single digit 'boost.' The proposed payment rate for CPT code 93229 for Zio AT mobile cardiac telemetry in the San Francisco geography was set at $1,083, a 2.7% boost compared to CY25, the analyst tells investors in a research note. The firm said this is a positive surprise since this code has been subject to relatively large cuts in recent years, adding that while the proposed rates are still subject to change, it does not make any changes to its estimates at this time. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with , delivered to your inbox every week.
Yahoo
14-07-2025
- Business
- Yahoo
iRhythm (IRTC) Stock Trades Up, Here Is Why
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 3.2% in the afternoon session after the positive sentiment from Wall Street analysts who saw further potential in the company. The digital healthcare firm has garnered a "Moderate Buy" consensus rating from analysts. Based on ten recent analyst ratings, the average twelve-month price target for iRhythm sits at $138.60, suggesting potential upside from its current trading level. Nine out of ten of these analysts rate the stock as a "Buy." This bullish stance from market experts likely reflects confidence in iRhythm's Zio service, a platform that uses wearable biosensors and cloud-based data analytics to diagnose cardiac arrhythmias. The company's focus on integrating artificial intelligence to provide clinically actionable insights for physicians positions it well within the growing digital health sector. After the initial pop the shares cooled down to $139.19, up 2.4% from previous close. Is now the time to buy iRhythm? Access our full analysis report here, it's free. iRhythm's shares are very volatile and have had 26 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. iRhythm is up 55.6% since the beginning of the year, but at $139.19 per share, it is still trading 10% below its 52-week high of $154.71 from June 2025. Investors who bought $1,000 worth of iRhythm's shares 5 years ago would now be looking at an investment worth $1,206. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-07-2025
- Business
- Yahoo
Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating
iRhythm Technologies, Inc. (NASDAQ:IRTC) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Morgan Stanley has raised its price target on iRhythm Technologies, Inc. (NASDAQ:IRTC) to $160 from $130, while maintaining an 'Overweight' rating, citing strong early indicators for the company's second-quarter performance. In a recent note to investors, the firm pointed to a surge in MyZio app downloads, which totaled 171,169 in Q2—up 74% year-over-year and 36% compared to the first quarter. The increase suggests iRhythm may outperform Street estimates, as most of the Zio patches generating revenue for the quarter have already been prescribed and tied to active monitoring. A patient being monitored with a portable ECG device, showing the effectiveness of the company's products. Morgan Stanley highlighted that the strong app adoption signals growing patient engagement and broader acceptance of digital cardiac care, which bodes well for both short- and long-term growth. With scalable infrastructure and a rising volume of clinical data feeding its algorithms, iRhythm is not only improving detection but also redefining remote patient monitoring. As healthcare shifts toward personalized, tech-driven models, iRhythm's innovation and execution place it among the leaders in digital diagnostics. Morgan Stanley views the company as a compelling investment amid increasing demand for smart, connected health solutions. iRhythm Technologies, Inc. (NASDAQ:IRTC) develops and markets the Zio platform, a patch-based cardiac monitoring solution that leverages advanced analytics and machine learning to detect arrhythmias with clinical-grade accuracy. The company's AI-enabled technology analyzes millions of heartbeats in real time, helping physicians diagnose conditions like atrial fibrillation more effectively than traditional methods. While we acknowledge the potential of IRTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IRTC and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
